Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
239
-
Total 13F shares, excl. options
-
35.4M
-
Shares change
-
+3.86M
-
Total reported value, excl. options
-
$1.5B
-
Value change
-
+$147M
-
Put/Call ratio
-
0.73
-
Number of buys
-
133
-
Number of sells
-
-93
-
Price
-
$42.41
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q1 2020
306 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q1 2020.
CRISPR Therapeutics AG - Common Stock (CRSP) has 239 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.4M shares
of 86M outstanding shares and own 41.16% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (4.29M shares), Versant Venture Management, LLC (4.21M shares), Nikko Asset Management Americas, Inc. (3.77M shares), NEA Management Company, LLC (2.09M shares), FEDERATED HERMES, INC. (1.08M shares), WADDELL & REED FINANCIAL INC (1.03M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.01M shares), FMR LLC (877K shares), CREDIT SUISSE AG/ (852K shares), and MORGAN STANLEY (852K shares).
This table shows the top 239 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.